Biogen at the brink, Pfizer’s big bet and other takeaways from a quiet JPM

A flurry of licensing deals kept things interesting.

READ MORE

JPMorgan Day 4: Talkspace plots comeback

The digital mental health company hit its share of potholes during 2021.

READ MORE

Medicare price negotiations, cancer care and ‘unintended consequences’

READ MORE

JPMorgan Day 3: Bluebird Bio preps for beti-cel launch

With its sickle-cell gene therapy stalled by FDA, the biotech is building for the potential debut of its one-and-done beta-thalassemia treatment, the CEO said.

READ MORE
Events
MM+M’s Women of Distinction
MM+M's newly revamped Women of Distinction offering celebrates the industry’s most successful and respected veteran leaders, while Women to Watch shines a light on its up-and-coming talent. Nominations will remain open until January 5, 2022.
LEARN MORE
Best Places to Work
In-office for culture and camaraderie. Remote for commute-free comfort. Can the business have its cake and eat it too?
Read the December Issue